← All trials
NCT05681312
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Dec 30, 2023
- Completion date
- Jan 1, 2024
- First posted
- Jan 12, 2023
- Last posted
- Aug 22, 2023
- Enrollment
- 55
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaghdadLead sponsor
- University of BaghdadReponsible party - principal investigator
- University of BaghdadStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.